View Older Stories View More Recent Stories
-
Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
-
Lumos Pharma, Inc. (LUMO) Announces $3M Share Buyback
-
Lumos Pharma Announces Share Repurchase Program
-
Lumos Pharma Announces Share Repurchase Program
-
Form 13F-HR DEERFIELD MANAGEMENT For: Jun 30
-
ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes
-
Miravo Healthcare™ Announces Second Quarter 2022 Results
-
Vigil Neuroscience (VIGL) Announces $75 Million Private Placement of Common Stock, Warrants
-
Vigil Neuroscience Announces $75 Million Private Placement Financing
-
Vigil Neuroscience Announces $75 Million Private Placement Financing
-
The Oncology Institute, Inc (TOI) Announces $110M Investment by Deerfield Management
-
The Oncology Institute Reports Second Quarter 2022 Financial Results and Reaffirms Full Year 2022 Guidance
-
The Oncology Institute Reports Second Quarter 2022 Financial Results and Reaffirms Full Year 2022 Guidance
-
The Oncology Institute announces $110 million strategic investment by Deerfield Management to accelerate its expansion into new markets
-
The Oncology Institute announces $110 million strategic investment by Deerfield Management to accelerate its expansion into new markets
-
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
-
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
-
Endologix Receives CE Mark Certification under EU-MDR for AFX®2 Endovascular AAA System
-
Element Science Announces First Patient Save with Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
-
NYC Healthcare Innovation Campus, Cure®, Fuels Economic Growth
-
Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease
-
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
-
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
-
Medical Microinstruments Secures $75M to Advance Robotic Microsurgery
-
Conventus Flower Orthopedics Appoints Bradley Niemann as Chief Executive Officer
-
Humanity Health Announces $6 Million Series A Funding Round
-
Apertura Appoints Gene Therapy Executive Joseph La Barge as Chief Executive Officer
-
Acutus Medical Completes First Closing of Transaction with Medtronic and Debt Refinancing to Fund Strategic Growth Priorities
-
Endologix Reports 12 Month Data from DETOUR 2 Clinical Trial at 2022 Vascular Annual Meeting
-
CobiCure launches to change the course of pediatric healthcare
-
Form 4 Nuvalent, Inc. For: Jun 16 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Form SC 13D/A CareMax, Inc. Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
EPIC SCIENCES RAISES $43M IN FIRST CLOSE OF SERIES F FINANCING TO ADVANCE COMPREHENSIVE PROFILING FOR METASTATIC CANCER PATIENTS
-
EPIC SCIENCES RAISES $42M IN FIRST CLOSE OF SERIES F FINANCING TO ADVANCE COMPREHENSIVE PROFILING FOR METASTATIC CANCER PATIENTS
-
Adela Initiates Key Study for Cancer Early Detection Program
-
Adela Announces Executive and Board of Directors Appointments and Formation of Scientific Advisory Board
-
Axon Therapies Announces Positive Early Clinical Data from REBALANCE-HF Randomized Clinical Trial
-
Biotech Acquisition (BIOT) and Blade Report Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat
-
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference
-
Perceive Biotherapeutics Appoints Anne E. Fung MD, as Chief Medical Officer to Drive Transformational Clinical Programs
-
Civetta Therapeutics Appoints Jesse Smith, Ph.D. as CSO and Susan Ashwell, Ph.D. as SVP of Chemistry
-
Form 13F-HR DEERFIELD MANAGEMENT For: Mar 31
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Blade Therapeutics (BIOT) Reports Data from Phase 1 and Preclinical Studies of Cudetaxestat
-
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
-
Miravo Healthcare™ Announces First Quarter 2022 Results
-
Form 4 Larimar Therapeutics, For: May 10 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
-
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates

